


An abstract painting of a landscape with rolling hills and mountains. The colors are vibrant and varied, including shades of purple, blue, green, yellow, and orange. The brushstrokes are visible, giving it a textured, expressive feel. The top of the image is a solid dark purple band.

Pharmacotherapeutics

Clinical Reasoning in Primary Care

2nd
Edition

Kathleen Gutierrez

SAUNDERS
ELSEVIER

evolve

<http://evolve.elsevier.com>

Contents

Unit I

FOUNDATIONS FOR PROFESSIONAL PRACTICE

CHAPTER 1

Introduction to Pharmacotherapeutics, 1

Kathleen Gutierrez

Historical Background, 1

- Mystical Period, 1
- Empirical Period, 1
- Medieval Period, 1
- Contemporary Period, 2

New Drug Development, 2

- Preclinical Development, 2
- Clinical Trials, 3
- Financing New Drug Development, 4

Naming New Drugs, 5

United States Drug Legislation, 5

- Federal Food, Drug, and Cosmetic Act, 6
- Sherley Amendment, 6
- Harrison Narcotic Act, 7
- Durham-Humphrey Amendment, 7
- Kefauver-Harris Amendment, 7
- Controlled Substances Act, 7

Canadian Drug Legislation, 8

- Canadian Food and Drugs Act, 8
- Narcotic Control Act, 9

Sources of Drug Information, 9

- Official Information Sources, 9
- Nonofficial Information Sources, 9

Key Points, 11

CHAPTER 2

Clinical Reasoning in Pharmacotherapeutics, 13

Kathleen Gutierrez

Pharmacotherapy as Art and Science, 13

Collaboration, 13

- Midlevel Providers, 13
- Associate Health Care Providers, 15

Clinical Reasoning, 15

Concepts and Principles of Prescribing, 20

- Types of Drug Orders, 20
- Essential Components of Drug Orders, 20
- Prescription Writing, 21
- Record-Keeping Requirements, 22
- Substitutions, 22
- Prescription Refills, 23
- Expired Prescriptions, 23
- Prescription Labeling, 23
- Prescription Copies, 24
- Out-of-State Prescriptions, 24
- Drug Samples, 24

Key Points, 24

CHAPTER 3

Pharmacoeconomics, 26

Kathleen Gutierrez

Philosophical Basis of Pharmacoeconomics, 26

- Resource Allocation, 26
- Increased Efficiency, 27

Pharmacoeconomics and Managed Care, 27

Perspectives, 28

- Society, 28
- Payor, 28
- Health Care Provider, 28
- Patient, 29

Pharmacoeconomics Study Designs, 29

- Cost-Benefit Analysis, 29
- Cost-Effectiveness Analysis, 29
- Cost-Utility Analysis, 30
- Cost-Minimization and Cost-of-Illness Analyses, 30

Analysis Strategies, 30

- Clinical Trials, 30
- Retrospective Database Analysis, 31
- Mathematical Modeling, 31

Methods for Pharmacoeconomic Analyses, 31

- Decision Analysis, 31
- Simulation Modeling, 32
- Statistical Analysis, 32

Pharmacoeconomics and Formularies, 33

- Pharmacy and Therapeutics Committees, 34

The Future of Pharmacoeconomics, 35

Key Points, 35

CHAPTER 4

Pharmaceutics and Pharmacokinetics, 37

Kathleen Gutierrez

Phases of Drug Activity, 37

- Pharmaceutic Phase, 37

Pharmacokinetic Phases, 38

- Absorption, 38
- Distribution, 43
- Biotransformation, 46
- Elimination, 49

Chronotherapy, 51

Key Points, 54

EVIDENCE-BASED PHARMACOTHERAPEUTICS

- Reliability of Different Formulae to Predict Creatinine Clearance, 53
-

CHAPTER 5

Pharmacodynamics, 56

Kathleen Gutierrez

Drug Actions Versus Drug Effects, 56

Drug Actions and Interactions, 56

- Receptor Theory of Drug Action, 56

- Receptor Types, 57
- Receptor Numbers and Response, 58
- Adverse Drug Reactions, 60**
 - Type 1 Adverse Reactions, 61
 - Type 2 Adverse Reactions, 62
 - Tolerance and Dependency, 63
- Drug Interactions, 64**
 - Additive Effects, 64
 - Synergism Versus Potentiation, 64
 - Drug-Food Interactions, 65
 - Drug-Herb Interactions, 65
 - Drug-Disease Interactions, 65
- Variables Affecting Drug Response, 65**
 - General State of Health, 65
 - Life-Span Considerations, 66
 - Body Weight, 66
 - Sex and Genetics, 66
 - Body Rhythms*, 66
 - Psychosocial Considerations, 67
 - Dietary Considerations, 67
 - Smoking and Alcohol Intake, 67
 - Environment, 67
 - Drug Additives and Bioavailability, 67
 - Dosage and Number of Drugs Administered, 67
 - Administration Routes and Techniques, 68
- Key Points, 68**

CHAPTER 6

Pharmacotherapeutics for Pregnant and Nursing Women, 70

Kathleen Gutierrez

- Anatomic and Physiologic Variables, 70**
 - Reproductive System, 70
 - Fluid Balance, 70
 - Gastrointestinal System, 70
 - Cardiovascular System, 71
 - Renal System, 71
 - Respiratory System, 71
 - Endocrine System, 71
- Maternal Pharmacokinetic Considerations, 72**
 - Absorption, 72
 - Distribution, 72
 - Biotransformation, 73
 - Elimination, 73
- Fetal-Placental Pharmacokinetic Considerations, 73**
 - Absorption, 73
 - Distribution, 73
 - Properties of Placenta, 73
 - Biotransformation, 75
 - Elimination, 75
- Pharmacodynamics, 75**
 - Teratogenesis, 75
- Drugs and Lactation, 77**
 - Minimizing Infant Drug Exposure, 77
- Clinical Reasoning, 78**
- Key Points, 80**
- CONTROVERSY Perinatal Pharmacotherapeutics—What to Restrict? 79**
 - Jonathan J. Wolfe*

CHAPTER 7

Pharmacotherapeutics for Children and Adolescents, 82

Ariys Williams

- Anatomic and Physiologic Variables, 82**
 - Body Composition and Size, 83
 - Fluid Balance, 83
 - Tissue Mass, 83
 - Head and Neck, 84
 - Respiratory System, 84
 - Cardiovascular System, 84
 - Gastrointestinal System, 84
 - Renal System, 85
 - Neurologic System, 85
 - Immune System, 85
- Pharmacokinetic Considerations, 85**
 - Absorption, 85
 - Distribution, 86
 - Biotransformation, 87
 - Elimination, 87
- Pharmacodynamic Considerations, 88**
- Clinical Reasoning, 88**
- Key Points, 89**
- CONTROVERSY Practical and Ethical Issues in Pediatric Clinical Trials, 82**

CHAPTER 8

Pharmacotherapeutics for Older Adults, 91

Kathleen Gutierrez

- The Complex Dynamics of Aging, 91**
 - Body Composition, 91
 - Cardiovascular System, 92
 - Respiratory System, 92
 - Gastrointestinal System, 92
 - Renal System, 93
 - Sensory-Perceptual Function, 93
 - Neuromuscular System, 93
 - Endocrine System, 93
 - Immune System 94
 - Mental Status, 94
- Pharmacokinetic Considerations, 94**
 - Absorption, 94
 - Distribution, 94
 - Biotransformation, 95
 - Elimination, 96
- Pharmacodynamic Considerations, 96**
- Clinical Reasoning, 97**
- Key Points, 101**
- EVIDENCE-BASED PHARMACOTHERAPEUTICS**
 - Estimating Glomerular Filtration Rate, 96
- CONTROVERSY Drugs and Driving? 97**
 - Jonathan J. Wolfe*

Unit II

COMMUNITY PHARMACOTHERAPEUTICS

CHAPTER 9

Over-the-Counter Drugs, 103

Elizabeth Wise Kissell

Consumer Buying Practices, 103

Trends in OTC Use, 103

Factors Influencing OTC Use, 104

Legislative Control of OTC Drugs, 105

OTC Categories, 105

Drug Labeling, 105

Drug Packaging, 106

Storage, Handling, and Disposal, 107

Storage, 107

Handling, 107

Disposal, 107

Adherence Versus Nonadherence, 108

Community Resources, 108

Community Pharmacists, 108

Computer Information Systems, 108

Publications, 109

Web-Based Resources, 110

Clinical Reasoning, 110

Management, 113

Key Points, 114

CONTROVERSY Why Do We Still Question the Use of

Generic Drugs? 112

Jonathan J. Wolfe

CHAPTER 10

Vitamins and Minerals, 115

Kathleen Gutierrez

Universal Considerations, 115

Classification of Vitamins, 115

Fat-Soluble Vitamins, 115

Water-Soluble Vitamins, 121

Minerals and Trace Elements, 127

Clinical Reasoning, 133

Key Points, 135

CONTROVERSY Dietary Supplements—Some Real

Issues, 135

Jonathan J. Wolfe

CHAPTER 11

Complementary and Alternative Medicine, 137

Kathleen Gutierrez

Epidemiology and Etiology of CAM, 137

Categories of CAM, 137

Legislation and Product Claims, 138

Health Claims, 138

Nutrient Claims, 138

Structure and/or Function Claims, 138

Labeling Issues, 138

Safety Issues, 138

Impurities, Adulterants, and Variability, 139

Formulation Issues, 139

Standardization of Herbals, 140

Phytomedicinal Options, 140

Clinical Reasoning, 153

Key Points, 156

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Cranberries for Urinary Tract Infections, 145

CONTROVERSY Unconventional Answers to Illness, 154

Jonathan J. Wolfe

CHAPTER 12

Substance Abuse, 158

Kathleen Gutierrez

Confusing Terminology, 158

Epidemiology of Substance Abuse, 160

At-Risk Populations, 160

War Veterans, 160

People with Chronic Pain, 160

Athletes, 161

Adolescents, 161

Older Adults, 161

Health Care Providers, 161

Commonly Abused Substances, 161

CNS Stimulants, 161

CNS Depressants, 166

Hallucinogens, 172

Other Substances of Abuse, 176

Clinical Reasoning, 177

Key Points, 180

CONTROVERSY Methadone: To Use or Not to Use, That is the Question, 170

CHAPTER 13

Poisonings, 182

Elizabeth Wise Kissell

Poisonings, 182

Epidemiology and Etiology, 182

Clinical Reasoning, 182

Key Points, 187

Unit III

DRUGS INFLUENCING THE AUTONOMIC NERVOUS SYSTEM

CHAPTER 14

Sympathetic Nervous System Drugs, 189

Kathleen Gutierrez

Functional Organization of the Nervous System, 189

Autonomic Nervous System, 189

Pharmacotherapeutic Options, 194

Adrenergic Agonists, 194

Adrenergic Blocking Drugs, 199

Clinical Reasoning, 199

Key Points, 200

CHAPTER 15

Parasympathetic Nervous System Drugs, 202

Kathleen Gutierrez

Physiology of Parasympathetic Neurotransmission, 202

Dementia of the Alzheimer's Type, 202

Epidemiology and Etiology, 202

Physiology and Pathophysiology, 203

Pharmacotherapeutic Options, 203

Cholinesterase Inhibitors, 203

N-methyl-D-aspartate (NMDA) Receptor Antagonist, 204

Clinical Reasoning, 205

Irritable Bowel Syndrome, 209

Pharmacotherapeutic Options, 209

Anticholinergics, 209

Clinical Reasoning, 211

Stimulation and Blockade of Ganglions, 212

Neuromuscular Blockade, 212

Pharmacotherapeutic Options, 213

Nondepolarizing Neuromuscular Blockers, 213

Depolarizing Neuromuscular Blocker, 213

Clinical Reasoning, 216

Key Points, 220

CONTROVERSY Clinical Trials Involving Alzheimer's

Disease Patients, 208

Sally Schnell

CASE STUDY Dementia of the Alzheimer's Type, 208

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Cholinesterase Inhibitor Treatment for Dementia of the Alzheimer's Type, 210

Unit IV

DRUGS INFLUENCING THE CENTRAL NERVOUS SYSTEM

CHAPTER 16

Opioid Analgesics and Related Drugs, 223

Sheryl J. Cator

Pain, 223

Epidemiology and Etiology, 223

Pathogenesis, 223

Pharmacotherapeutic Options, 225

Opioid Analgesics, 225

Mixed Opioid Agonists-Antagonists, 230

Nonopioid Analgesic, 231

Clinical Reasoning, 233

Key Points, 242

CONTROVERSY Administering Opioids to Chemically

Dependent Patients, 230

CASE STUDY Postoperative Analgesia, 235

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Management of Acute and Chronic Pain, 238

CHAPTER 17

NSAIDs, DMARDs, and Related Drugs, 244

Sheryl J. Cator

Pathogenesis of Inflammation, 244

Types of Inflammation, 244

Pharmacotherapeutic Options, 247

Nonsteroidal Antiinflammatory Drugs, 247

Clinical Reasoning, 256

Rheumatoid Arthritis, 260

Epidemiology and Etiology, 262

Pathophysiology, 262

Pharmacotherapeutic Options, 262

Disease-Modifying Antirheumatic Drugs, 262

Clinical Reasoning, 271

Gout, 272

Epidemiology and Etiology, 272

Pathophysiology, 272

Pharmacotherapeutic Options, 273

Antigout Drugs, 273

Uricosuric Drugs, 274

Newer Drugs for Gout, 275

Clinical Reasoning, 276

Key Points, 277

EVIDENCE-BASED PHARMACOTHERAPEUTICS

NSAIDs and Myocardial Infarction, 249

CONTROVERSY Salicylates and Reye's Syndrome: When to Use Aspirin? 257

Jonathan J. Wolfe

CASE STUDY Disease-Modifying Antirheumatic Drugs, 261

CHAPTER 18

Anesthetics, 279

Kathleen Gutierrez

Pharmacotherapeutic Options, 279

Infiltrative Anesthetics, 279

Conscious Sedation, 284

Pharmacotherapeutic Options, 284

Benzodiazepine and Opioid Combinations, 284

General Anesthesia, 285

Pharmacotherapeutic Options, 285

Barbiturates, 285

Opioid Antagonists, 286

Miscellaneous Injectables, 287

Reversal Drugs, 288

Neuromuscular Blockers, 288

Nondepolarizing Neuromuscular Blockers, 290

Inhalational Anesthesia, 291

Clinical Reasoning, 294

Key Points, 297

CONTROVERSY Appropriateness of Increased Utilization of Propofol in Anesthesia, 288

Jonathan J. Wolfe

CHAPTER 19

Antianxiety and Sedative-Hypnotic Drugs, 299

Kathleen Gutierrez

Anxiety, Sleep, and Other Disorders, 299

Epidemiology and Etiology, 299

Pathogenesis of Anxiety and Sleep Disorders, 302

Pharmacotherapeutic Options, 303

Benzodiazepines, 303

Atypical Anxiolytic, 306

Other Sedative-Hypnotics, 310

Barbiturates, 311

Clinical Reasoning, 311

Key Points, 318

EVIDENCE-BASED PHARMACOTHERAPEUTICS Use of Antidepressants in the Treatment of Generalized Anxiety Disorder, 305
CONTROVERSY Appropriate Use of Antianxiety Drugs, 312
Jonathan J. Wolfe
CASE STUDY Sedative-Hypnotics, 313

CHAPTER 20

Antidepressant and Antimania Drugs, 320

Kathleen Gutierrez

Depression, 320

Epidemiology and Etiology, 320
Pathophysiology, 320
Pharmacotherapeutic Options, 321
Selective Serotonin Reuptake Inhibitors, 321
Serotonin-Norepinephrine Reuptake Inhibitors, 325
Tricyclic Antidepressants, 327
Monoamine Oxidase Inhibitors (MAOIs), 330
Miscellaneous Antidepressants, 330

Clinical Reasoning, 332

Bipolar Disorder, 339

Epidemiology and Etiology, 339
Pathophysiology, 339
Pharmacotherapeutic Options, 339
Mood-Stabilizing Drugs, 339

Clinical Reasoning, 342

Key Points, 346

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Continuation of SSRI Therapy Versus Therapy with TCAs, 322

CASE STUDY Antidepressants, 333

CONTROVERSY Antidepressants for Adolescents: Good or Bad? 335

CASE STUDY Mood-Stabilizing Drugs, 343

CHAPTER 21

Antipsychotic Drugs, 348

Kathleen Gutierrez

Schizophrenia, 348

Epidemiology and Etiology, 348
Pathophysiology, 348
Pharmacotherapeutic Options, 349
First-Generation Antipsychotic Drugs, 349
Second-Generation Antipsychotic Drugs, 353

Clinical Reasoning, 356

Key Points, 361

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Antipsychotic Drug Therapy, 357

CONTROVERSY Diagnostic Approach to Schizophrenia, 360

CHAPTER 22

Central Nervous System Stimulants, 363

Sean M. Reed

Narcolepsy, 363

Epidemiology and Etiology, 363
Pathophysiology, 363

Attention Deficit Hyperactivity Disorder, 363

Epidemiology and Etiology, 363
Pathophysiology, 365
Exogenous Obesity, 365
Epidemiology and Etiology, 365
Pathophysiology, 365
Pharmacotherapeutic Options, 365
Psychomotor Stimulants, 365
Anorexants, 367
Analeptics, 367

Clinical Reasoning, 370

Key Points, 372

CASE STUDY Central Nervous System Stimulants, 364

CONTROVERSY Long-Term Safety and Effectiveness of CNS Stimulants, 370

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Methylphenidate for Adults with Attention Deficit Hyperactivity Disorder, 372

CHAPTER 23

Skeletal Muscle Relaxants, 374

Kathleen Gutierrez

Spasm Versus Spasticity, 374

Epidemiology and Etiology, 374
Pathophysiology, 374
Pharmacotherapeutic Options, 375
Centrally Acting Drugs, 375
Peripherally Acting Drugs, 378

Clinical Reasoning, 381

Key Points, 387

CONTROVERSY Intrathecal Baclofen in Cerebral Palsy, 378

Jonathan J. Wolfe

CASE STUDY Centrally Acting Skeletal Muscle Relaxants, 379

CASE STUDY Peripherally Acting Skeletal Muscle Relaxants, 382

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Noninvasive Treatments for Nonspecific Low Back Pain, 384

CHAPTER 24

Drugs Used for Migraines, 389

Kathleen Gutierrez

Headaches, 389

Epidemiology and Etiology, 389
Pathophysiology, 389
Pharmacotherapeutic Options, 390
Serotonin Agonists, 390
Ergot Alkaloids, 394
Migraine Prophylaxis Drugs, 397

Clinical Reasoning, 397

Key Points, 404

CASE STUDY Drugs Used for Migraines, 392

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Neurophins and Migraines, 394

CHAPTER 25

Antiepileptic Drugs, 406

Kathleen Gutierrez

Epilepsy, 406

Epidemiology and Etiology, 406

Pathophysiology, 406

Pharmacotherapeutic Options, 407

Hydantoins, 407

Valproates, 413

Other Antiepileptic Drugs, 413

Barbiturates, 419

Benzodiazepines, 420

Clinical Reasoning, 420

Key Points, 426

CONTROVERSY Drug Errors from Confusing Orders and New Drugs, 408

Jonathan J. Wolfe

EVIDENCE-BASED PHARMACOTHERAPEUTICS Rapid Versus Slow Withdrawal of Antiepileptic Drugs, 423

CASE STUDY Antiepileptic Drugs, 424

CHAPTER 26

Drugs for Parkinson's Disease and Myasthenia Gravis, 427

Kathleen Gutierrez

Parkinson's Disease, 427

Epidemiology and Etiology, 427

Physiology and Pathophysiology, 427

Pharmacotherapeutic Options, 429

Dopaminergic Drugs, 429

Dopamine Agonists, 432

Anticholinergics, 434

Monoamine Oxidase B Inhibitors, 435

Catechol-O-Methyltransferase (COMT) Inhibitor, 436

Clinical Reasoning, 437

Myasthenia Gravis, 442

Epidemiology and Etiology, 442

Pathophysiology, 443

Pharmacotherapeutic Options, 445

Cholinesterase Inhibitors, 445

Corticosteroids, 446

Immunosuppressants, 448

Clinical Reasoning, 450

Key Points, 454

CASE STUDY Drugs for Parkinson's Disease, 438

EVIDENCE-BASED PHARMACOTHERAPEUTICS Coffee and Caffeine Intake and Risk for Parkinson's Disease, 443

CASE STUDY Drugs for Myasthenia Gravis, 450

Unit V

DRUGS INFLUENCING THE IMMUNE SYSTEM

CHAPTER 27

Antibiotics, 457

Kathleen Gutierrez

Bacterial Infections, 457

Epidemiology and Etiology, 457

Pathophysiology, 457

Principles of Antibiotic Therapy, 460

Site and Host Defenses, 460

The Infecting Organism, 460

Drug Action, 460

Susceptibility and Sensitivity, 460

Antibiotic Resistance, 460

Pharmacotherapeutic Options, 462

Penicillins, 462

Cephalosporins, 464

Sulfonamides, 468

Tetracyclines, 471

Aminoglycosides, 473

Quinolones, 475

Macrolides, 476

Carbapenems, 478

Miscellaneous Antibiotics, 480

Clinical Reasoning, 482

Key Points, 488

CONTROVERSY Should Health Care Providers Perform Diagnostic Tests on Patients Before Prescribing Antibiotics? 483

Jonathan J. Wolfe

CASE STUDY Antibiotics—Soft Tissue Infection, 484

CHAPTER 28

Antiviral and Antifungal Drugs, 490

Kathleen Gutierrez

Introduction to Viruses, 490

Influenza, 491

Epidemiology and Etiology, 491

Pathophysiology, 491

Pharmacotherapeutic Options, 492

Neuramidase Inhibitors, 492

Adamantane Derivatives, 493

Clinical Reasoning, 495

HIV and AIDS, 498

Epidemiology and Etiology, 498

Pathophysiology, 499

Pharmacotherapeutic Options, 501

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, 501

Nucleotide Reverse Transcriptase Inhibitor (NtRTI), 501
Nnucleoside Reverse Transcriptase Inhibitors (NNRTIs), 503

Protease Inhibitors, 505

HIV Fusion Inhibitor, 506

Clinical Reasoning, 507

Herpes, Varicella, and CMV Retinitis, 514

Herpesvirus Infections, 514

Invasive CMV Retinitis, 515

Fungal Infections, 517

Epidemiology and Etiology, 517

Pathophysiology, 517

Pharmacotherapeutic Options, 518

Polyene Antifungals, 518

Triazole Antifungals, 519

Imidazole Antifungals, 525

Allylamines, 526

Glucan Synthesis Inhibitors, 527

Miscellaneous Antifungals, 527

Clinical Reasoning, 528

Key Points, 530

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Virucidal Nasal Tissues, 498

CASE STUDY Antiviral Drugs, 508

CONTROVERSY Ethical Challenges in HIV Treatment of the Homeless, 513

CONTROVERSY Using Topical Antifungal and Antiviral Drugs, 529

Jonathan J. Wolfe

CHAPTER 29

Antitubercular and Antileprotic Drugs, 533

Kathleen Gutierrez

Tuberculosis, 533

Epidemiology and Etiology, 533

Pathophysiology, 533

Pharmacotherapeutic Options, 535

First-Line Drugs, 536

Second-Line Drugs, 540

Clinical Reasoning, 541

Leprosy, 546

Epidemiology and Etiology, 546

Pathophysiology, 547

Pharmacotherapeutic Options, 548

First-Line Drugs, 548

On the Horizon, 550

Clinical Reasoning, 550

Key Points, 553

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Levofloxacin for Active Tuberculosis? 536

CASE STUDY Antitubercular Drugs, 543

CONTROVERSY Directly Observed Therapy for Tuberculosis, 546

Sandra Franklin

CASE STUDY Antileprotic Drugs, 551

CHAPTER 30

Anthelmintic, Antimalarial, and Antiprotozoal Drugs, 555

Kathleen Gutierrez

Helminthiasis, 555

Epidemiology and Etiology, 555

Pathophysiology, 558

Pharmacotherapeutic Options, 558

Clinical Reasoning, 563

Malaria, 564

Epidemiology and Etiology, 564

Pathophysiology, 564

Pharmacotherapeutic Options, 564

Clinical Reasoning, 568

Amebiasis, 571

Epidemiology and Etiology, 571

Pathophysiology, 571

Pharmacotherapeutic Options, 571

Giardiasis, 572

Pharmacotherapeutic Options, 572

Leishmaniasis, 573

Pharmacotherapeutic Options, 573

Ectoparasites, 573

Pediculosis, 573

Scabies, 574

Pharmacotherapeutic Options, 574

Key Points, 576

CASE STUDY Antimalarial Drugs, 569

CASE STUDY Antiprotozoal Drugs, 574

CHAPTER 31

Sera, Vaccines, and Other Immunizing Drugs, 578

Elizabeth Wise Kissell

Immunity, 578

Types of Immunity, 578

Drugs for Active Immunity, 580

Diseases and Drugs of Active Immunity, 582

Drugs for Passive Immunity, 589

Travel Immunizations, 590

Clinical Reasoning, 592

Legal Implications of Immunizing, 594

Bioterrorism, 596

Diseases and Drugs of Bioterrorism, 596

Key Points, 600

CONTROVERSY Immunization Policy Issues, 592

Jonathan J. Wolfe

CHAPTER 32

Biologic Response Modifiers, 603

Sheryl J. Cator

Categories of BRMs, 605

Pathogenesis, 605

Pharmacotherapeutic Options, 607

Interferons, 607

Interleukins, 608

Colony-Stimulating Factors, 612

Monoclonal Antibodies, 613

Miscellaneous BRMs, 614

Clinical Reasoning, 618

Key Points, 620

CONTROVERSY Tumor Necrosis Factor- α Antagonists: Helpful or Harmful? 619

CHAPTER 33

Antineoplastic Drugs, 622

Reamer L. Bushardt

Cancer, 622

Epidemiology and Etiology, 622

Pathophysiology, 623

Antineoplastic Dosing Regimens, 626

Pharmacotherapeutic Options, 627

Drugs Interacting with DNA Synthesis: Alkylating
Drugs, 627

Drugs Damaging DNA: Antimetabolites, 632

Drugs Damaging DNA: Antimitotic Drugs, 634

Drugs Damaging DNA: Topoisomerase Inhibitors, 635

Drugs Damaging DNA: Antitumor Antibiotics, 636

Miscellaneous Antineoplastic Drugs, 637
Hormones and Hormone Antagonists, 638
Other Types of Cancer Drug Therapies, 640

Clinical Reasoning, 641

Key Points, 647

Unit VI

DRUGS INFLUENCING THE CARDIOVASCULAR SYSTEM

CHAPTER 34

Inotropic Drugs, 649

Kathleen Gutierrez

Heart Failure, 649

Epidemiology and Etiology, 649

Pathophysiology, 650

Pharmacotherapeutic Options, 651

Angiotensin-Converting Enzyme Inhibitors, 652

Angiotensin Receptor Blockers, 652

Beta Blockers, 652

Vasodilators, 654

Cardiac Glycoside, 654

Phosphodiesterase Inhibitors, 657

On the Horizon, 659

Clinical Reasoning, 659

Key Points, 663

CASE STUDY Inotropic Drugs, 660

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Phosphodiesterase Inhibitors, 662

CONTROVERSY Inotropics: Expectations and Limitations, 663

Jonathan J. Wolfe

CHAPTER 35

Antianginal Drugs, 665

Kathleen Gutierrez

Angina Pectoris, 665

Epidemiology and Etiology, 665

Pathophysiology, 665

Pharmacotherapeutic Options, 667

Nitrates, 667

Beta Blockers, 671

Calcium Channel Blockers, 672

Angiotensin-Converting Enzyme Inhibitors, 673

Antianginal and Antiischemic Drug, 673

Clinical Reasoning, 674

Key Points, 680

CASE STUDY Antianginal Drugs, 674

CHAPTER 36

Antiarrhythmic Drugs, 681

Reamer L. Bushardt

Arrhythmias, 681

Epidemiology and Etiology, 681

Pharmacotherapeutic Options, 684

Class I_A Antiarrhythmics, 684

Class I_B Antiarrhythmics, 687

Class I_C Antiarrhythmics, 693

Class II Antiarrhythmics, 694

Class III Antiarrhythmics, 695

Class IV Antiarrhythmics, 698

Miscellaneous Antiarrhythmics, 698

Clinical Reasoning, 699

Key Points, 704

EVIDENCE-BASED PHARMACOTHERAPEUTICS Cardiac

Arrhythmia Suppression Trial, 694

CASE STUDY Atrial Fibrillation, 700

CONTROVERSY Antiarrhythmics: Good versus Harm, 702

Jonathan J. Wolfe

CHAPTER 37

Antihypertensive Drugs, 706

Kathleen Gutierrez

Hypertension, 706

Epidemiology and Etiology, 706

Pathophysiology, 707

Pharmacotherapeutic Options, 708

Diuretics, 708

Beta-Adrenergic Blockers, 709

Angiotensin-Converting Enzyme Inhibitors, 711

Angiotensin II-Receptor Blockers, 714

Calcium Channel Blockers, 716

Alpha₁ Receptor Blockers, 716

Central Alpha₂-Receptor Agonists, 716

Adrenergic Antagonists, 717

Direct-Acting Peripheral Vasodilators, 717

Newer Antihypertensives, 719

Clinical Reasoning, 721

Key Points, 731

CASE STUDY Antihypertensive Drugs, 723

CONTROVERSY Initial Use of Diuretics and Beta Blockers, 726

Jonathan J. Wolfe

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Depression and Hypertension, 731

CHAPTER 38

Antilipidemic Drugs, 733

Kathleen Gutierrez

Hyperlipoproteinemia, 733

Epidemiology and Etiology, 733

Pathophysiology, 733

Pharmacotherapeutic Options, 737

HMG-CoA Reductase Inhibitors, 737

Cholesterol Absorption Inhibitor, 738

Bile Acid Resins, 739

Fibric Acid Derivatives, 741

Niacin, 741

Omega-3 and Omega-6 Fatty Acids, 742

Miscellaneous Antilipidemic Drugs, 743

Clinical Reasoning, 744

Key Points, 750

CONTROVERSY Diet versus Drugs in Treating Hyperlipidemia, 746

Jonathan J. Wolfe

CASE STUDY Antilipemic Drugs, 747

Unit VII

DRUGS INFLUENCING THE HEMATOLOGIC SYSTEM

CHAPTER 39

Anticoagulant and Antiplatelet Drugs, 753

Kathleen Gutierrez

Thromboembolic Disease, 753

Epidemiology and Etiology, 753

Physiology and Pathophysiology, 753

Pharmacotherapeutic Options, 754

Anticoagulants, 754

Newer Anticoagulants, 761

Antiplatelet Drugs, 763

Clinical Reasoning, 765

Key Points, 769

CASE STUDY Anticoagulant and Antiplatelet Drugs, 765

CONTROVERSY How Safe Is Anticoagulation Therapy? 767

Jonathan J. Wolfe

CHAPTER 40

Thrombolytic and Sclerosing Drugs, 771

Reamer L. Bushardt

Cardiovascular Disorders, 771

Cerebrovascular Accident, 771

Epidemiology and Etiology, 771

Pathophysiology, 771

Myocardial Infarction, 771

Epidemiology and Etiology, 771

Pathophysiology, 772

Pulmonary Embolism, 772

Epidemiology and Etiology, 772

Pathophysiology, 773

Peripheral Vascular Occlusion, 773

Epidemiology and Etiology, 773

Pathophysiology, 773

Central Venous Access Occlusion, 773

Pharmacotherapeutic Options, 773

Thrombolytics, 773

Clinical Reasoning, 776

Lower Extremity and Esophageal Varices, 779

Epidemiology and Etiology, 779

Pathophysiology, 779

Pharmacotherapeutic Options, 779

Sclerosing Drugs, 779

Clinical Reasoning, 780

Key Points, 783

CASE STUDY Thrombolytics, 781

Unit VIII

DRUGS INFLUENCING THE GENITOURINARY SYSTEM

CHAPTER 41

Urinary Antimicrobials and Related Drugs, 785

Sean M. Reed

Urinary Tract Infections, 785

Epidemiology and Etiology, 785

Pathophysiology, 786

Pharmacotherapeutic Options, 788

Sulfonamides, 788

Quinolones, 790

Urinary Tract Antiseptics, 791

Clinical Reasoning, 792

Key Points, 797

CASE STUDY Urinary Antimicrobial and Related Drugs, 793

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Antibiotic Therapies for Urinary Tract Infections, 795

CONTROVERSY Cranberry Juice: Effective or Ineffective? 796

CHAPTER 42

Diuretics, 799

Kathleen Gutierrez

Renal Function, 799

Fluid Volume Excess, 799

Epidemiology and Etiology, 799

Pathophysiology, 800

Pharmacotherapeutic Options, 802

Thiazides, 802

Thiazide-Like Diuretics, 802

Potassium-Sparing Diuretics, 806

Loop Diuretics, 807

Osmotic Diuretics, 808

Clinical Reasoning, 809

Key Points, 813

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Thiazides and the Risk for Hip Fracture, 803

CASE STUDY Diuretics, 809

CONTROVERSY Diuretics: Drugs of Abuse? 811

CHAPTER 43

Drugs Used for Bladder, Prostate, and Erectile Dysfunction, 815

Kathleen Gutierrez

Overactive Bladder, 815

Epidemiology and Etiology, 815

Pathophysiology, 815

Pharmacotherapeutic Options, 815

Antimuscarinic Drugs, 815

Clinical Reasoning, 817

Benign Prostatic Hyperplasia, 820

Epidemiology and Etiology, 820

Pathophysiology, 820

Pharmacotherapeutic Options, 821

Alpha Blockers, 821

5 α -Reductase Inhibitors, 821

Clinical Reasoning, 822

Urinary Retention, 824

Epidemiology and Etiology, 824

Pathophysiology, 825

Pharmacotherapeutic Options, 825

Muscarinic Agonist, 825

Clinical Reasoning, 826

Miscellaneous Urinary Drugs, 827

Urinary Tract Antispasmodics, 827

Urinary Tract Analgesic, 828

Erectile Dysfunction, 828

Epidemiology and Etiology, 828

Pathophysiology, 828
Pharmacotherapeutic Options, 829
Phosphodiesterase Inhibitors, 829
Miscellaneous Drugs for Erectile Dysfunction, 831

Clinical Reasoning, 831

Key Points, 832

**EVIDENCE-BASED PHARMACOTHERAPEUTICS The
MTOPS Trial, 823**

**EVIDENCE-BASED PHARMACOTHERAPEUTICS
Sildenafil for Pulmonary Hypertension, 830**

CHAPTER 44

Drugs Used for Renal Dysfunction, 834

Kathleen Gutierrez

Acute Renal Failure, 834

Epidemiology and Etiology, 834

Pathophysiology, 834

Chronic Renal Failure, 834

Epidemiology and Etiology, 834

Pathophysiology, 835

Pharmacotherapeutic Options, 836

Angiotensin-Converting Enzyme Inhibitors, 836

Angiotensin II–Receptor Blockers, 836

Antianemics, 837

Iron Supplements, 840

Antihemorrhagic Drugs, 843

Phosphate-Binding Drugs, 843

Vitamin D Supplements, 844

Heavy Metal Antagonist, 845

Cation-Exchange Resins, 845

Systemic Antacids, 846

Diuretics, 846

Renal Vasodilator, 846

Clinical Reasoning, 846

Key Points, 850

**EVIDENCE-BASED PHARMACOTHERAPEUTICS BMI
and Risk for ESRD, 850**

Unit IX

DRUGS INFLUENCING THE GASTROINTESTINAL SYSTEM

CHAPTER 45

Drugs for Hyperacidity, Gastroesophageal Reflux Disease, and Peptic Ulcer Disease, 853

Kathleen Gutierrez

Gastroesophageal Reflux Disease, 853

Epidemiology and Etiology, 853

Pathophysiology, 853

Peptic Ulcer Disease, 854

Epidemiology and Etiology, 854

Pathophysiology, 854

Pharmacotherapeutic Options, 855

Proton Pump Inhibitors, 855

Histamine₂-Receptor Antagonists, 857

Nonsystemic Antacids, 861

Prostaglandin, 862

Prokinetic Drug, 863

Cytoprotective Drug, 863

Clinical Reasoning, 864

Key Points, 873

**CONTROVERSY Self-Treating with OTC Antisecretory
Drugs, 860**

Jonathan J. Wolfe

EVIDENCE-BASED PHARMACOTHERAPEUTICS Short

Term Treatment of Gastroesophageal Reflux, 868

CASE STUDY Proton Pump Inhibitors, 869

CASE STUDY *H. pylori* Drug Therapy, 871

CHAPTER 46

Laxatives and Antidiarrheal Drugs, 875

Martha A. Spangler

Constipation, 875

Epidemiology and Etiology, 875

Pathophysiology, 875

Pharmacotherapeutic Options, 875

Bulk-Forming Laxatives, 875

Stool Softeners, 876

Osmotic Laxatives, 878

Stimulant Laxatives, 881

Miscellaneous Laxatives, 882

Clinical Reasoning, 883

Diarrhea, 885

Epidemiology and Etiology, 885

Pathophysiology, 886

Pharmacotherapeutic Options, 886

Opioid Antidiarrheals, 886

Absorbents, 887

Miscellaneous Antidiarrheal Drugs, 888

Clinical Reasoning, 889

Key Points, 892

**EVIDENCE-BASED PHARMACOTHERAPEUTICS Therapy
for Irritable Bowel Syndrome, 877**

CASE STUDY Laxatives, 890

**CONTROVERSY Pepto-Bismol, Loperamide, and
Diarrhea, 892**

Jonathan J. Wolfe

CHAPTER 47

Antiemetics and Related Drugs, 894

Martha A. Spangler

Nausea and Vomiting, 894

Epidemiology and Etiology, 894

Pathophysiology, 894

Pharmacotherapeutic Options, 894

Antihistamines, 894

Serotonin Antagonists, 896

Phenothiazines, 900

Prokinetic Drug, 900

Cannabinoids, 901

Miscellaneous Drugs, 901

Benzodiazepines, 902

Corticosteroids, 902

Clinical Reasoning, 902

Key Points, 906

CASE STUDY Antiemetics, 905

CHAPTER 48

Cation-Exchange Resins and Ammonia-Detoxifying Drugs, 908

Kathleen Gutierrez

Hyperkalemia, 908

Epidemiology and Etiology, 908

Pathophysiology, 908

Pharmacotherapeutic Options, 909

Cation-Exchange Resins, 909

Clinical Reasoning, 911

Hepatic Encephalopathy, 912

Epidemiology and Etiology, 912

Pathophysiology, 912

Pharmacotherapeutic Options, 913

Ammonia-Detoxifying Drugs, 913

Clinical Reasoning, 916

Key Points, 916

CASE STUDY Ammonia-Detoxifying Drugs, 914

CHAPTER 49

Alkalinizing and Acidifying Drugs, 918

Kathleen Gutierrez

Acid-Base Balance and Imbalance, 918

Bicarbonate-Carbonic Acid Buffer System, 918

Hemoglobin, 918

Phosphate Buffer System, 918

Respiratory System, 918

Renal System, 918

Pathophysiology of Alkalosis and Acidosis, 920

Pharmacotherapeutic Options, 921

Alkalinizing Drugs, 921

Acidifying Drugs, 922

Clinical Reasoning, 924

Key Points, 927

Unit X

DRUGS INFLUENCING THE RESPIRATORY SYSTEM

CHAPTER 50

Antiasthmatic and Bronchodilator Drugs, 929

Gail Ladean Cross

Asthma, 929

Epidemiology and Etiology, 929

Pathophysiology, 929

Pharmacotherapeutic Options, 930

Inhaled Corticosteroids, 930

Beta Agonists, 932

Leukotriene Antagonists, 936

Antiallergy Drugs, 937

Xanthine Derivatives, 937

Antimuscarinic Drugs, 938

Monoclonal Antibody, 939

Clinical Reasoning, 939

Key Points, 949

CASE STUDY Antiasthmatic and Bronchodilator Drugs, 942

CHAPTER 51

Antihistamines and Related Drugs, 951

Gail Ladean Cross

Rhinitis, 951

Epidemiology and Etiology, 951

Pathophysiology, 952

Pharmacotherapeutic Options, 953

Intranasal Corticosteroids, 953

H₁ Antagonists, 954

Cromolyn Sodium, 958

Clinical Reasoning, 958

Key Points, 962

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Pediatric Allergic Rhinitis and Nasal Irrigation, 959

CASE STUDY Antihistamines, 959

CHAPTER 52

Decongestants, Expectorants, Antitussives, and Mucolytics, 964

Martha A. Spangler

Common Cold, 964

Epidemiology and Etiology, 964

Pathophysiology, 964

Pharmacotherapeutic Options, 965

Oral and Intranasal Decongestants, 965

Expectorants, 966

Antitussives, 968

Mucolytics, 969

Miscellaneous Respiratory Drugs, 970

Clinical Reasoning, 970

Key Points, 976

CASE STUDY Common Cold, 973

CONTROVERSY Effectiveness of Over-the-Counter Drugs for Coughs and Congestion, 974

Jonathan J. Wolfe

EVIDENCE-BASED PHARMACOTHERAPEUTICS

Over-the-Counter Formulations for Acute Cough, 975

Unit XI

DRUGS INFLUENCING THE ENDOCRINE SYSTEM

CHAPTER 53

Drugs Used in the Treatment of Diabetes Mellitus, 977

Margaret Elaine McLeod

Diabetes Mellitus, 977

Epidemiology and Etiology, 977

Pathophysiology, 977

Pharmacotherapeutic Options, 978

Insulins, 978

Recombinant Human Insulin Inhalation Powder, 981

Biguanides, 982

Thiazolidinediones, 983

Sulfonylureas, 984

Meglitinide Analogues, 988

Alpha-Glucosidase Inhibitors, 988

Amylin Agonists, 989
Incretin Mimetic, 990
Incretin Inhibitors, 992
Insulin Antagonist, 993
Nutritive Agents, 994
Clinical Reasoning, 994
Key Points, 1001
EVIDENCE-BASED PHARMACOTHERAPEUTICS Interim
Analysis of Effects of Exenatide, 991
CASE STUDY Drugs Used to Treat Diabetes, 997

CHAPTER 54

Thyroid and Parathyroid Drugs and Drugs for Calcium Disorders, 1003

Kathleen Gutierrez

Hypothyroidism, 1003

Epidemiology and Etiology, 1003
Pathophysiology, 1004
Pharmacotherapeutic Options, 1004
Thyroid Replacement Hormones, 1004

Clinical Reasoning, 1006

Hyperthyroidism, 1011

Epidemiology and Etiology, 1011
Pathophysiology, 1012
Pharmacotherapeutic Options, 1012
Antithyroid Drugs, 1012
Radioactive Iodine, 1013

Clinical Reasoning, 1014

Hypoparathyroidism, 1016

Epidemiology and Etiology, 1016
Pathophysiology, 1016
Pharmacotherapeutic Options, 1017
Calcium Salts, 1017
Vitamin D and Vitamin D Analogues, 1018

Clinical Reasoning, 1019

Hyperparathyroidism, 1020

Epidemiology and Etiology, 1020
Pathophysiology, 1021

Clinical Reasoning, 1021

Osteoporosis, 1022

Epidemiology and Etiology, 1022
Pathophysiology, 1023
Pharmacotherapeutic Options, 1023
Bisphosphonates, 1023
Selective Estrogen Receptor Modulators, 1024
Hormone Modifier Drugs, 1024
Miscellaneous Hypocalcemic Drugs, 1025

Clinical Reasoning, 1026

Key Points, 1031

CASE STUDY Thyroid and Parathyroid Drugs, 1010

CASE STUDY Drugs for Calcium Disorders, 1028

EVIDENCE-BASED PHARMACOTHERAPEUTICS Cost Effectiveness of Alendronate Therapy, 1029

CHAPTER 55

Pituitary Drugs, 1033

Kathleen Gutierrez

Pituitary Physiology, 1033

Pituitary Dysfunction, 1034

Epidemiology and Etiology, 1034

Pharmacotherapeutic Options, 1034

Anterior Pituitary Hormone Replacement Drugs, 1034

Posterior Pituitary Hormone Replacement Drugs, 1037

Hormone Inhibitor Drugs, 1039

Clinical Reasoning, 1040

Key Points, 1043

CASE STUDY Pituitary Drugs, 1042

CHAPTER 56

Adrenal Cortex Agonists and Inhibitors, 1045

Kathleen Gutierrez

Adrenal Insufficiency, 1045

Epidemiology and Etiology, 1045
Pathophysiology, 1045
Pharmacotherapeutic Options, 1046
Glucocorticoids, 1046
Mineralocorticoids, 1049

Clinical Reasoning, 1051

Adrenal Hypersecretion, 1056

Epidemiology and Etiology, 1056
Pathophysiology, 1056
Pharmacotherapeutic Options, 1057
Adrenal Corticosteroid Inhibitors, 1057

Clinical Reasoning, 1058

Key Points, 1058

CASE STUDY Adrenal Cortex Agonists, 1053

CHAPTER 57

Androgens and Anabolic Steroids, 1060

Christina J. Hanson

Hypogonadism, 1060

Epidemiology and Etiology, 1060
Pathophysiology, 1060
Pharmacotherapeutic Options, 1062
Androgens, 1062
Newer Androgens, 1064

Clinical Reasoning, 1065

Hereditary Angioedema, 1066

Epidemiology and Etiology, 1066
Pathophysiology, 1066
Pharmacotherapeutic Options, 1067
Anabolic Steroids, 1067

Clinical Reasoning, 1068

Key Points, 1071

CASE STUDY Androgens, 1061

CONTROVERSY Androgens and Anabolic Steroids: Not Just in Pro Sports, 1068

Jonathan J. Wolfe

CASE STUDY Anabolic Steroids, 1069

CHAPTER 58

Hormonal Contraceptives and Related Drugs, 1072

Christine C. Hansen

Menstrual Cycle, 1072

Ovulatory Response, 1072
Endometrial Response, 1073

Changes at Puberty, 1074	
Changes at Menopause, 1074	
Menstrual Cycle Disruptions, 1075	
Amenorrhea, 1075	
Dysmenorrhea, 1075	
Premenstrual Syndrome, 1075	
Abnormal Uterine Bleeding, 1075	
<i>Pharmacotherapeutic Options, 1075</i>	
Estrogens, 1075	
Progestins, 1077	
Hormonal Contraceptives, 1080	
Clinical Reasoning, 1085	
Key Points, 1093	
CONTROVERSY Hormonal Contraceptives, 1088	
<i>Jonathan J. Wolfe</i>	
EVIDENCE-BASED PHARMACOTHERAPEUTICS	
Long-Term Hormone Therapy, 1088	
CASE STUDY Hormonal Therapy, 1090	
CHAPTER 59	
Uterine Motility Drugs, 1095	
<i>Kathleen Gutierrez</i>	
Physiology of Labor, 1095	
Initiation of Labor, 1095	
Stages of Labor, 1095	
<i>Pharmacotherapeutic Options, 1096</i>	
Uterine Stimulant, 1096	
Prostaglandins, 1097	
Ergot Alkaloids, 1100	
Preterm Labor, 1100	
<i>Pharmacotherapeutic Options, 1100</i>	
Beta Agonists, 1100	
Miscellaneous Drugs, 1102	
Drugs to Improve Neonatal Outcomes, 1102	
Clinical Reasoning, 1102	
Key Points, 1104	
CONTROVERSY Uterine Motility Drugs, 1101	
<i>Jonathan J. Wolfe</i>	
CHAPTER 60	
Fertility Drugs, 1106	
<i>Kathleen Gutierrez</i>	
Infertility, 1106	
Epidemiology and Etiology, 1106	
Pathophysiology, 1106	
Assistive Reproduction, 1109	
<i>Pharmacotherapeutic Options, 1110</i>	
Nonsteroidal Antiestrogen Drug, 1110	
Gonadotropins, 1111	
Gonadotropin-Releasing Hormone Analogue, 1114	
Dopamine Agonist, 1116	
Adjunctive Therapies, 1117	
Clinical Reasoning, 1117	
Key Points, 1120	
CONTROVERSY The Ethics of Using Fertility Drugs, 1118	
<i>Jonathan J. Wolfe</i>	
CASE STUDY Fertility Drugs, 1119	

Unit XII

DRUGS INFLUENCING THE SENSORY SYSTEM

CHAPTER 61

Ophthalmic Drugs, 1123

Elizabeth Wise Kissell

Pharmacokinetics of Ophthalmic Drugs, 1123

Absorption, 1123

Distribution, 1123

Biotransformation and Elimination, 1124

Ocular Infections, 1124

Etiology, 1124

Pathophysiology, 1125

Pharmacotherapeutic Options, 1126

Antibiotics, 1126

Antivirals, 1127

Antifungal Drugs, 1127

Antiprotozoal Drugs, 1127

Ocular Inflammation and Allergies, 1127

Pharmacotherapeutic Options, 1128

Nonsteroidal Antiinflammatory Drugs, 1128

Corticosteroids, 1128

Antihistamines, 1128

Glaucoma, 1129

Epidemiology and Etiology, 1129

Pathophysiology, 1130

Pharmacotherapeutic Options, 1132

Ophthalmic Beta Blockers, 1132

Prostaglandin Analogues, 1133

Carbonic Anhydrase Inhibitors, 1134

Ophthalmic Adrenergics, 1136

Cholinergic Miotics, 1137

Anticholinesterase Miotics, 1137

Ophthalmic Anticholinergics, 1138

Diagnostic Aids, 1138

Ocular Anesthetics, 1139

Lubricants, 1139

Ocular Irrigants, 1139

Clinical Reasoning, 1139

Key Points, 1144

CASE STUDY Ophthalmic Drugs, 1140

EVIDENCE-BASED PHARMACOTHERAPEUTICS Patient Preferences for Eye Drop Characteristics, 1143

CHAPTER 62

Otic Drugs, 1146

Elizabeth Wise Kissell

Infection, 1146

Epidemiology and Etiology, 1146

Pathophysiology, 1146

Pharmacotherapeutic Options, 1146

Antibiotics, 1146

Acidifying Solutions, 1147

Inflammation and Pain, 1147

Epidemiology and Etiology, 1147

Pathophysiology, 1148

Pharmacotherapeutic Options, 1148

Steroids and Steroid-Antibiotic and Steroid-Antifungal
Combinations, 1148

Otic Anesthetics, 1149

Cerumen Impaction, 1149

Epidemiology and Etiology, 1149

Pathophysiology, 1149

Pharmacotherapeutic Options, 1150

Ceruminolytics, 1150

Ototoxicity, 1150

Clinical Reasoning, 1151

Key Points, 1154

CASE STUDY Otic Drugs, 1153

CHAPTER 63

Dermatologic Drugs, 1155

Kathleen Gutierrez

Structure and Functions of the Skin, 1155

Epidermis, 1155

Dermis, 1155

Soft Tissues, 1155

Skin Disorders, 1156

Noninfectious Inflammatory Dermatoses, 1156

Infectious Inflammatory Dermatoses, 1158

Drug Reactions, 1160

Infestations and Bites, 1160

Trauma, 1160

Burns, 1161

Decubitus Ulcers, 1162

Pharmacotherapeutic Options, 1162

Pharmacokinetics, 1162

Clinical Reasoning, 1167

Key Points, 1172

CASE STUDY Dermatologic Drugs, 1168

CONTROVERSY Dermatologic Drugs, 1170

Jonathan J. Wolfe

INDEX, 1175